N/A N=15 Human Papillomatosis Genotyping of Children in Thailand
Recurrent Laryngeal Papillomatosis · Human Papilloma Virus
Primary: Human Papillomavirus Genotypes — 6; 9 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 4 N=19 Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Phase 2 N=21 Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
Recurrent Respiratory Papillomatosis
Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants
Phase 2 N=9 M7824 in People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Respiratory Papillomatosis · Laryngeal Papilloma, Recurrent
Primary: Proportion of Participants With a Complete Response — 0; 0 proportion of participants
N/A N=156 Typing of Human Papilloma Virus (HPV) From Female Genital Warts
Genital Warts · Human Papilloma Virus
Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants
Phase 1 N=20 Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis
Primary: The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient…
Phase 2 N=13 Avelumab for People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Juvenile Laryngeal Papilloma · Laryngeal Papilloma, Recurrent
Primary: Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated…
Phase 2 N=32 INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Respiratory Papillomatosis
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 33.3; 66.7; 75.0; 62.5 percentage of participants
Phase 2 N=41 Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline — -5.4; -15.2 percent change in mean growth rate — p=0.57
N/A N=328 Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis
Lichen Sclerosus · Lichen Planus · Lichen Simplex Chronicus
Primary: Diagnostic Accuracy of "Three Rings Vulvoscopy" by the "Vulvoscopy Index" for Detection of Vulvar Dermatosis — 72; 0; 10; 246 Participants — p=0.6108
N/A N=150 Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
Condylomata Acuminata
Primary: Human Papillomavirus (HPV) Types in External Genital Warts (EGW) — 80; 12.66; 0.66; 2 percentage of participants
Phase 2 N=56 Cantharidin and Occlusion in Verruca Epithelium
Common Wart · Warts Hand · Warts
Primary: Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) — 4 Participants
N/A N=24 Nanopulse Efficacy Study for the Treatment of Common Warts
Common Warts
Primary: Clinical Clearance of Warts — 13; 4; 2 # of warts
N/A N=127 The Human Papilloma Virus Effect on Sexual Life
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
N/A N=72 Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
Skin Lesion · Skin Abnormalities · Sebaceous Hyperplasia
Primary: Total Number of Cleared SH Lesions — 99.5 Percentage of cleared SH Lesions
Phase 2 N=35 De-Escalation Therapy for Human Papillomavirus Negative Disease
Human Papilloma Virus · Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck
Primary: Deep Response Rate (DRR) — 16; 19 Participants
Phase 4 N=225 HPV Vaccination Study in Postpartum Women
HPV · Immunization · Human Papilloma Virus
Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL
N/A N=329 Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela
Cervical Cancer
Primary: HPV Identification — 95; 142; 78 biopsies
N/A N=122 Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy
Barrett Syndrome · Barrett's Syndrome · Barrett's Esophagus
Primary: Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of…
Phase 2 N=29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
N/A N=756 Pap Smear Collection With the Papette Brush
Cervical Cancer Screening
Primary: Specimen Adequacy — 335; 371 Participants — p=.75
Phase 2 N=15 Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
Oral Cavity Carcinoma · Oral Intraepithelial Neoplasia
Primary: Oral Cancer-free Survival — NA; 6.7 Months